Bintou A. Ahidjo

NUSMed Biosafety Level 3 Core Facility, 14 Medical Drive
Singapore, 117599, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants.

Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants.

Journal: Pharmaceutics
Published: December 12, 2022

Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling.

Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling.

Journal: Indoor air
Published: April 26, 2021

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Journal: PloS one
Published: February 04, 2021

A blood RNA transcriptome signature for COVID-19.

A blood RNA transcriptome signature for COVID-19.

Journal: BMC medical genomics
Published: January 20, 2021

MIC Ranges of Quality Control Strain Mycobacterium peregrinum ATCC 700686 against Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline.

MIC Ranges of Quality Control Strain Mycobacterium peregrinum ATCC 700686 against Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline.

Journal: Journal of clinical microbiology
Published: October 15, 2020

Current Perspective of Antiviral Strategies against COVID-19.

Current Perspective of Antiviral Strategies against COVID-19.

Journal: ACS infectious diseases
Published: June 03, 2020

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.

Journal: The Lancet. Respiratory medicine
Published: February 14, 2020

The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

Journal: JCI insight
Published: October 05, 2016

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.

Journal: EBioMedicine
Published: March 17, 2016

Erratum to "Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis" [EBioMedicine 2 (8), August 2015, 868-873].

Erratum to "Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis" [EBioMedicine 2 (8), August 2015, 868-873].

Journal: EBioMedicine
Published: February 13, 2016

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.

Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: September 03, 2015

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.

Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.

Journal: EBioMedicine
Published: April 24, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026